Mon, Jul 14, 2014, 11:42 AM EDT - U.S. Markets close in 4 hrs 18 mins

Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • billyteex1 billyteex1 Jul 25, 2007 4:11 PM Flag

    PHRM

    Sales were 32.5M up from 31.3M on Vidaza.

    They also increased the EU sales to 8m from 6.4m.

    We could see next quarter about 3M in outside U.S. sales and a extra $675,000 per quarter sales increase. This would add a penny to EPS. I got my estimate from what vidaza started off outside U.S. and I believe JNJ is larger and has better connections.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • BOULDER, Colo., July 25 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM - News) today reported financial results for its quarter ended June 30, 2007. Second quarter net sales totaled $65.8 million, compared to $60.4 million in the second quarter of 2006. Worldwide sales of Vidaza� (azacitidine for injection) totaled $40.5 million in the second quarter of 2007, compared to $36.1 million in the same quarter of 2006. In the U.S., sales of Vidaza totaled $32.5 million in the second quarter of 2007, compared to $33.7 million in the same quarter of 2006, reflecting relatively constant sales despite the entry of two competitive products to the U.S. Myelodysplastic Syndromes (MDS) market during 2006. Named patient and compassionate use sales of Vidaza in Europe and other international markets totaled $8.0 million in the second quarter of 2007, compared to $2.4 million in the second quarter of 2006. Sales of Thalidomide, including named patient and compassionate use sales in Europe, totaled $20.4 million in the second quarter of 2007, compared to $19.1 million in the same period of 2006.